A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Clinical Trial Opens for Patients with High-Grade Neuroendocrine Cancer - InventUM
The TEM8 protein coded by the ANTXR1 gene represents an emerging biomarker in solid tumors. In addition to the various roles TEM8 plays in oncogenesis, including angiogenesis, epithelial-to-mesenchymal transition, and cell migration, it has also been shown that the overexpression of the ANTXR1 gene in solid tumors correlates with poor prognostic indicators in several solid tumor histologies. As such, TEM8 has been identified as the target of novel oncologic therapies. It is especially attractive given its selective expression on the surface of solid tumor cells and associated stromal cells, such as cancer stem cells, invasive cancer cells, and immune cells, such as macrophages, angiogenic endothelial cells, pericytes, and cancer-associated fibroblasts. Furthermore, TEM8 plays this unique role as a mostly non-mutated gene in solid cancers. Here, we demonstrate that elevated expression of ANTXR1 in bladder cancer showed a statistical difference not only in overall survival (OS) but in progression-free survival (PFS), confirming the prognostic biomarker power of ANTXR1 expression.
Authors include Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics
November 15, 2023 06:00 AM Eastern Standard Time
PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc., announced today the publication of “TEM8 in Oncogenesis” in Cells. The authors are Dr. Samuel Kareff and Dr. Aman Chauhan from Sylvester Cancer at University of Miami, Dr. Virginia Corbett from Mt. Sinai Tisch Cancer Center and Dr. Paul Hallenbeck from Seneca Therapeutics.
“In the article, we underline TEM8’s prognostic and predictive abilities in various solid tumors by (1) highlighting its association with more aggressive disease biology and poor clinical outcomes and (2) assessing its associated clinical trial landscape,” said Dr. Aman Chauhan. “Finally, we offer future directions for clinical studies involving TEM8, including incorporating preclinical agents into clinical trials and combining previously tested oncologic therapies with currently available treatments, such as immunotherapy.”
“The evidence of TEM8’s abilities and role in a broad range of solid tumors continues to grow,” said Dr. Paul Hallenbeck. “This review article provides an excellent update on both TEM8, ANTXR1 - the gene that encodes TEM8 - and SVV-001 which targets TEM8. This update provides a foundation for upcoming publications and clinical trials for SVV-001 and TEM8.”
Seneca Therapeutics is developing SVV-001, a number of SVV-001 armed constructs and a multiple IV option for SVV-001 sensitive solid tumors. SVV-001 sensitivity is defined as high ANTXR1 (TEM8) expression and a microtumor environment which permits replication of SVV-001 in the tumor. Seneca has developed an SVV-001 Companion Diagnostic and received FDA clearance to use it in clinical trials to identify patients that would benefit from SVV-001.
About Seneca Therapeutics
Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 that create additional anti-tumor effects.
Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.
Paul Hallenbeck
CSO and President
phallenbeck@senecatherapeutics.com
James Hussey
CEO
jhussey@senecatherapeutics.com
www.senecatherapeutics.com
